Cytiva v. JSR Corporation: Federal Circuit Splits on Protein A Chromatography Patent
Cytiva Bioprocess R&D AB and JSR Corporation clashed at the Federal Circuit over US10875007B2, a patent covering a domain C protein A chromatography ligand central to antibody purification manufacturing. After 497 days, the court issued a mixed ruling — affirming in part and reversing in part — a split outcome that reshapes the enforceability landscape for both parties.
A split Federal Circuit ruling reshapes a key antibody purification patent
Cytiva Bioprocess R&D AB, a leading bioprocess technology company and holder of US10875007B2, brought this infringement action against JSR Corporation and its affiliate JSR Life Sciences LLC. The patent at issue covers a chromatography ligand incorporating domain C from Staphylococcus aureus protein A — a technology central to the industrial purification of therapeutic antibodies. The appeal was filed on July 26, 2023 before the Court of Appeals for the Federal Circuit.
The Federal Circuit closed the case on December 4, 2024 with an order affirmed-in-part and reversed-in-part, with the appeal also dismissed in part. This mixed disposition means some aspects of the lower tribunal’s findings were upheld — carrying full precedential weight for those issues — while others were overturned, potentially reopening questions of infringement, validity, or claim scope for the reversed portions. The partial dismissal further indicates that certain grounds were not adjudicated on their merits.
A 497-day appellate timeline is broadly consistent with Federal Circuit norms for technically complex biotechnology disputes. The split outcome suggests the court found merit in arguments on both sides, which is relatively uncommon and typically signals genuine legal ambiguity in claim construction or validity analysis. The precise scope of what was affirmed versus reversed is not fully discernible from the public record alone, leaving the ultimate commercial impact on JSR’s chromatography product line uncertain pending further proceedings.
Filing to Appeal Dismissed in Part in 497 days
497 days from filing to Federal Circuit decision — consistent with complex biotech appeals
Federal Circuit’s split decision: what affirmed-in-part, reversed-in-part means
What ‘affirmed-in-part, reversed-in-part’ means at the Federal Circuit
An affirmed-in-part, reversed-in-part disposition means the Federal Circuit found no reversible error in some aspects of the lower decision, while finding that other aspects were legally or factually incorrect. Neither party achieved a clean win. The affirmed portions stand as final; the reversed portions may require remand or further proceedings to resolve outstanding issues of infringement or validity.
Split appellate dispositionCytiva retains partial victory but faces uncertainty on reversed issues
For Cytiva, the affirmance on certain issues preserves enforceable rights under US10875007B2 in those respects — a meaningful result for a patent covering core antibody purification technology. However, the reversal on other issues suggests Cytiva did not fully vindicate its infringement or validity positions. The scope of remaining enforceable claims may be narrower or different than originally asserted, requiring careful reassessment of enforcement strategy.
Partial enforceability retainedJSR wins reversal on key issues but cannot claim full clearance
JSR Corporation and JSR Life Sciences secured a reversal on at least part of the lower decision — a significant appellate result that may clear certain infringement findings or validity determinations against them. The partial dismissal further limits Cytiva’s ability to press some claims. However, the affirmance of remaining issues means JSR still faces live exposure under the patent on those grounds and cannot claim complete freedom to operate without further legal clarity.
Partial reversal securedSplit ruling prolongs IP uncertainty in the protein A chromatography market
Protein A affinity chromatography is the dominant platform for monoclonal antibody purification — a multi-billion-dollar manufacturing segment. A split Federal Circuit ruling on the core domain C ligand patent creates continued ambiguity for competitors and suppliers designing around or licensing this technology. Companies relying on similar chromatography ligand architectures should monitor any remand proceedings closely, as the final scope of US10875007B2 remains unsettled.
Sector uncertainty continuesFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Cytiva Bioprocess R & D, AB | Individual | Bioprocess technology firm — holder of US10875007B2 (protein A chromatography ligand)Search in Eureka ↗ |
| Defendant | JSR Corporation | Company | JSR Corporation and JSR Life Sciences LLC — specialty materials and life sciences companiesSearch in Eureka ↗ |
| Co-Defendant | Jsr Life Sciences, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | David M. Krinsky | Attorney | Counsel for Cytiva Bioprocess R & D, ABSearch in Eureka ↗ |
| Plaintiff law firm | Williams & Connolly LLP | Law Firm | Representing Cytiva Bioprocess R & D, ABSearch in Eureka ↗ |
| Defendant counsel | Eric William Dittmann Esq. | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Hiroyuki Hagiwara | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Isaac S. Ashkenazi Esq. | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Michael Wolfe | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Naveen Modi | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Phillip W. Citroen | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Stephen Blake Kinnaird | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant law firm | Paul Hastings Foreign Law Joint Enterprise | Law Firm | Representing JSR CorporationSearch in Eureka ↗ |
| Defendant law firm | Paul Hastings LLP | Law Firm | Representing JSR CorporationSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘AFFIRMED-IN-PART AND REVERSED-IN-PART’ — reflects a nuanced appellate review applying de novo standards to claim construction and substantial evidence review to factual findings. This phrasing confirms the court identified at least one reversible error in the lower decision while upholding other determinations. The accompanying partial dismissal suggests procedural or jurisdictional bars prevented merits review of certain issues. The net effect is a fragmented enforceability profile for US10875007B2 that neither party can fully rely upon without further proceedings.
US10875007B2 — Protein A domain C chromatography ligand for antibody isolation
US10875007B2 (application number US16/443600) protects a chromatography ligand incorporating domain C derived from Staphylococcus aureus protein A. Protein A affinity chromatography is the gold-standard method for isolating and purifying monoclonal antibodies in biopharmaceutical manufacturing. The domain C variant is significant because modifications to protein A domains affect binding affinity, stability under alkaline cleaning conditions, and resin lifetime — all commercially critical parameters for large-scale mAb production.
This patent sits at the intersection of bioprocess engineering and biopharmaceutical manufacturing infrastructure. Holders of strong protein A ligand patents can command licensing revenues across the mAb supply chain — from resin manufacturers to contract development and manufacturing organisations. Cytiva’s enforcement of this patent against JSR, a significant materials science and life sciences group, underscores how foundational chromatography IP is becoming a competitive battleground as biosimilar and novel antibody pipelines expand globally.
Should you run an FTO analysis against US10875007B2?
Any organisation developing, manufacturing, or supplying protein A-based affinity chromatography resins — particularly those utilising domain C or engineered variants thereof — should treat US10875007B2 as a priority FTO target. The Federal Circuit’s split ruling means some claims remain enforceable while others may be narrowed or invalidated. This creates both risk and opportunity: the precise claim scope post-appeal is not yet settled, and working products in this space could still fall within surviving claims.
PatSnap Eureka’s FTO Search Agent can map the current enforceability landscape of US10875007B2 against your specific chromatography ligand architecture. By combining claim-level analysis with the post-appeal prosecution history and related family members, Eureka helps your R&D and IP teams identify freedom-to-operate risks before product launch — and surface design-around opportunities informed by the reversed claim elements from this Federal Circuit decision.
Run a freedom-to-operate analysis on US10875007B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit patent appeals in bioprocess chromatography
Explore Federal Circuit patent appeals involving protein A chromatography, bioprocess ligand technology, and antibody purification — the same technical domain at issue in Cytiva v. JSR.
What this case signals for the bioprocess chromatography IP landscape
Federal Circuit splits on a foundational antibody purification patent — downstream implications for mAb manufacturers and chromatography suppliers.
Protein A ligand patents remain highly litigable at the Federal Circuit
The willingness of the Federal Circuit to reverse in part suggests genuine claim construction or validity disputes exist around domain C protein A ligand patents. Companies holding or challenging similar bioprocess patents should anticipate extended appellate timelines and the possibility of split outcomes that require further proceedings to resolve commercial uncertainty.
Partial dismissal limits the scope of what was decided on the merits
The ‘dismissed in part’ component means some grounds were never adjudicated. For IP strategists, this is a signal that the public record does not capture the full picture of the dispute. Any freedom-to-operate analysis referencing this case must account for issues that were dismissed without merits resolution — those questions may resurface in future litigation.
AB v JSR — key questions answered
The Federal Circuit issued an affirmed-in-part and reversed-in-part decision on December 4, 2024, with the appeal also dismissed in part. This means some aspects of the lower ruling on US10875007B2 were upheld while others were overturned. The precise claims affected are not fully detailed in the public docket entry alone.
US10875007B2 covers a chromatography ligand comprising domain C from Staphylococcus aureus protein A, used for antibody isolation. Protein A affinity chromatography is the dominant platform for purifying monoclonal antibodies in biopharmaceutical manufacturing. Patents on engineered domain C variants are strategically important because they affect resin performance, alkaline stability, and production economics at commercial scale.
A split disposition means US10875007B2 remains enforceable in the respects affirmed by the Federal Circuit, while the reversed portions may no longer support the original infringement or validity findings. The patent is not wholly invalidated or wholly vindicated. Parties relying on this case for FTO purposes should conduct claim-level analysis to identify which aspects survived appellate review.
The public record indicates the appeal was ‘dismissed in part,’ suggesting that certain issues raised on appeal were barred from merits review — potentially due to procedural grounds, lack of appellate jurisdiction over specific issues, or waiver. This means those issues were not decided on the substance, and the lower decision on those points may stand by default without full appellate endorsement.
Yes. The split ruling creates ongoing uncertainty for companies supplying or designing protein A affinity resins based on domain C architectures. The affirmed issues sustain Cytiva’s enforcement rights in those respects; the reversed issues may open design-around opportunities. Suppliers should conduct updated FTO analysis against US10875007B2 in light of the post-appeal claim scope before making product or commercialisation decisions.
PatSnap Eureka searches patents and litigation data to answer instantly.